Xiangxue Pharmaceutical Co.,Ltd.

300147

CNE100000Y92

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3.67 ^CNY	-1.87%		+1.66%	-28.74%

Apr. 29	Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ji Qingsong agreed to acquire 18.87% stake in Hubei Tianji Pharmaceutical Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. for CNY 200 million.

August 01, 2023

Ji Qingsong agreed to acquire 18.87% stake in Hubei Tianji Pharmaceutical Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) for CNY 200 million on August 2, 2023. As on June 30, 2023, Hubei Tianji Pharmaceutical Co., Ltd. generated total assets of CNY 2.2 billion and net assets of CNY 1.05 billion. The transacttion is approved by board of directors of Xiangxue Pharmaceutical Co.,Ltd.

Latest news about Xiangxue Pharmaceutical Co.,Ltd.

Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Ji Qingsong agreed to acquire 18.87% stake in Hubei Tianji Pharmaceutical Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. for CNY 200 million.	23-08-01	CI
Xiangxue Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 959.884 million in funding	23-08-01	CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-21	CI
Xiangxue Pharma Trims Losses in 2022	23-01-24	MT
China's COVID scare sparks run on flu medicines, test kits as far away as Australia	22-12-15	RE
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Wuhan Yiyi Tongguan Enterprise Management Partnership (Limited Partnership) and Hubei Qingsong Yueyue Pharmaceutical Co., Ltd. agreed to acquire 35% stake in Hubei Tianji Pharmaceutical Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. for CNY 385 million.	22-06-30	CI
Xiangxue Pharmaceutical Co.,Ltd. Approves Board Elections	22-06-27	CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-22	CI
Xiangxue Pharmaceutical Unlocks 3.4 Million Restricted Shares; Shares Rally 13%	22-01-03	MT
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
Xiangxue Pharma's Shareholder Scraps Stake Sale Plan	21-07-25	CI
Guangdong Hengshu No. 1 Investment Partnership Enterprise (Limited Partnership) cancelled the acquisition of a 9.98% stake in Xiangxue Pharmaceutical Co.,Ltd. from Guangzhou Kunlun Investment Co., Ltd.	21-07-22	CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI
Xiangxue Pharmaceutical Co.,Ltd. signed the share transfer agreement to acquire Guangzhou Xiehe Precision Medical Co., Ltd. from Guangzhou Kunlun Investment Co., Ltd. for CNY 1.5 billion.	21-03-26	CI
Guangdong Hengshu No. 1 Investment Partnership Enterprise (Limited Partnership) signed an agreement to acquire a 9.98% stake in Xiangxue Pharmaceutical Co.,Ltd. from Guangzhou Kunlun Investment Co., Ltd. for approximately CNY 390 million.	21-03-09	CI
Suzhou Sirnaomics Biopharmaceuticals Co., Ltd signed share purchase agreement to acquire 4.2% stake in Guangzhou Nanotides Pharmaceuticals Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. for CNY 2.2 million.	21-01-24	CI

Chart Xiangxue Pharmaceutical Co.,Ltd.

Duration

Period

More charts

Company Profile

XIANGXUE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the research, development, production and distribution of traditional Chinese medicines and herbal decoction pieces. The Company's main products include antiviral oral liquids, indigowoad root granules, Exocarpium Citri Reticulatae series Chinese patent drugs and herbal decoction pieces, among others. The Company is also involved in the manufacture and sale of medical devices, health products, soft drinks and biological products. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
XIANGXUE PHARMACEUTICAL CO.,LTD.	-28.74%	335M
DONG-E-E-JIAO CO.,LTD.	+39.33%	6.11B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-18.38%	4.35B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.17%	3.18B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+3.98%	3.15B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.41%	2.51B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+48.74%	1.98B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-4.82%	1.74B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-1.24%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-8.96%	1.6B